Literature DB >> 11592850

Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

J C Liévens1, B Woodman, A Mahal, O Spasic-Boscovic, D Samuel, L Kerkerian-Le Goff, G P Bates.   

Abstract

Huntington's disease (HD) is a late-onset neurodegenerative disease for which the mutation is CAG/polyglutamine repeat expansion. The R6 mouse lines expressing the HD mutation develop a movement disorder that is preceded by the formation of neuronal polyglutamine aggregates. The phenotype is likely caused by a widespread neuronal dysfunction, whereas neuronal cell death occurs late and is very selective. We show that a decreased mRNA level of the major astroglial glutamate transporter (GLT1) in the striatum and cortex of these mice is accompanied by a concomitant decrease in glutamate uptake. In contrast, the expression of the glutamate transporters, GLAST and EAAC1, remain unchanged. The mRNA level of the astroglial enzyme glutamine synthetase is also decreased. These changes in expression occur prior to any evidence of neurodegeneration and suggest that a defect in astrocytic glutamate uptake may contribute to the phenotype and neuronal cell death in HD. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592850     DOI: 10.1006/nbdi.2001.0430

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  106 in total

1.  Brain endothelial cells induce astrocytic expression of the glutamate transporter GLT-1 by a Notch-dependent mechanism.

Authors:  Meredith L Lee; Zila Martinez-Lozada; Elizabeth N Krizman; Michael B Robinson
Journal:  J Neurochem       Date:  2017-09-05       Impact factor: 5.372

2.  Deletion of astroglial Dicer causes non-cell-autonomous neuronal dysfunction and degeneration.

Authors:  Jifang Tao; Hao Wu; Quan Lin; Weizheng Wei; Xiao-Hong Lu; Jeffrey P Cantle; Yan Ao; Richard W Olsen; X William Yang; Istvan Mody; Michael V Sofroniew; Yi E Sun
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

3.  Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC.

Authors:  Jason M B Wilson; Iraj Khabazian; David V Pow; Ulla K Craig; Christopher A Shaw
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 4.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

5.  Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease.

Authors:  Junmei Wan; Jeffrey N Savas; Amy F Roth; Shaun S Sanders; Roshni R Singaraja; Michael R Hayden; John R Yates; Nicholas G Davis
Journal:  Chem Biol       Date:  2013-11-07

6.  Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Courtney L Burroughs; Stephen Cavaliere; Scott J Barton; Shirley Chen; X William Yang; George V Rebec
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

7.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Authors:  Andrew M Tidball; Miles R Bryan; Michael A Uhouse; Kevin K Kumar; Asad A Aboud; Jack E Feist; Kevin C Ess; M Diana Neely; Michael Aschner; Aaron B Bowman
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

8.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms.

Authors:  Jennifer Bradford; Ji-Yeon Shin; Meredith Roberts; Chuan-En Wang; Xiao-Jiang Li; Shihua Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

9.  Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.

Authors:  Geraldine T Petr; Laurel A Schultheis; Kayla C Hussey; Yan Sun; Janet M Dubinsky; Chiye Aoki; Paul A Rosenberg
Journal:  Eur J Neurosci       Date:  2013-04-16       Impact factor: 3.386

10.  Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease.

Authors:  Birgit Zucker; Dagmar E Ludin; Thomas A Gerds; Carl H Lücking; G Bernhard Landwehrmeyer; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.